This webinar will discuss a variety of topics in the management of an advanced heart failure patient. The use of contemporary therapies such as ARNI, SGLTI, novel anticoagulants, amiodarone, ablation, and inotropes in a heart transplant or LVAD candidate, and the potential implications on transplantation and durable LVAD outcomes. Attendees will gain practical insights from expert speakers on the use of these HF therapies in patients awaiting heart transplantation or durable LVAD therapy.
 

Scientific Program

Moderators:
Tara Veasey, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA USA
Carlos Ortiz Bautista MD, PhD, Hospital General Universitario Gregorio Marañón, Madrid Spain
Alina Nicoara, MD, Duke University, Durham, NC, USA

Advanced Heart Failure: Too Advanced for Quadruple Therapy?
Georgina Waldman, PharmD, BCTXP, Massachusetts General Hospital, Boston, MA USA
This presentation will discuss the role evidence for current standard of care in HF therapy medications (beta blockers, ARM, ARNI, MRA and SGLTI) in advanced HF patients, and the risks/ considerations specific to the advanced HF patient listed for transplant e.g., SGLT2 inhibitors and ketoacidosis. Can we extrapolate from clinical trials to advanced HF?

Adjuvant’ Therapy in Advanced Heart Failure: Short Term Gain And Longer-Term Pain?
Doug Jennings, PharmD, NY Presbyterian Hospital / Columbia University, New York, NY USA
This presentation will review considerations for ’adjuvant’ medications typically used in advanced heart failure and transplant candidates, including anti-arrhythmic (e.g. amiodarone), antiplatelets (DAPT e.g. recent PCI), anticoagulants (in particular DOACS: AntiXa and direct thrombin inhibitors in those listed for MCS or Transplant), and inotropes. Do short term benefits outweigh post-transplant risks?

Just Small Adults? Managing Advanced Heart Failure In Children And Congenital Heart Disease
Paul Kantor, MBBCh, MSc, FRCPC, University of Southern California / Children's Hospital Los Angeles, CA USA
This presentation will describe an overview of specifics of heart failure management in children, the underlying pediatric evidence and adaption and divergence of evidence generated in adult trials. It will further outline aspects of heart failure management in adults and children with congenital hearts disease including single ventricle and failing Fontan physiology.

Everything Short of Mechanical Circulatory Support: Devices and Interventions for Advanced Heart Failure
Guillaume Coutance, MD, Pitié-Salpetrière Hospital, Paris, France
This presentation will discuss if should we go straight to transplant or LVAD, or is there a role for valve intervention, ablation (VT, AV node+CRT) and other devices in advanced HF/ transplant candidates. Devices in advanced HF (resynchcronisation, edge to edge for mitral or tricuspid).

Q&A Discussion with All Speakers
Led by Moderators
 

Continuing Education Information

There will be no continuing education available for this webinar.